Abstract 22P
Background
To date, empirical methods using age, type of cancer and presence of family history of cancers are used clinically to identify individuals who may benefit from genetic counselling (GC) and testing, but because these guidelines use a threshold, they provide a standard recommendation regardless of whether women have a low (e.g. 4%) or high (e.g. 40%) likelihood of being BRCA carriers. We developed the Asian Genetic Risk Calculator (ARiCa), an Asian-specific personalised genetic risk assessment tool, to determine the probability of a breast cancer patient carrying a germline BRCA1/2 pathogenic or likely pathogenic variant. The ARiCa Study was established to evaluate the impact of personalised risk score on risk perception and cancer-related distress, and uptake of GC among breast cancer patients.
Methods
The ARiCa Study is a prospective observational multicentre two-arm study where 256 incident and prevalent breast cancer patients in breast surgical clinics who have previously not received GC will be randomised to receive genetic risk assessment based on current clinical criteria (controls) or ARiCa personalised risk score. The patients’ risk perception, distress level and GC uptake were determined via researcher-administered questionnaires six weeks after risk assessment.
Results
Interim analysis of 110 patients showed that compared to controls, a greater proportion of patients receiving ARiCa scores felt that the genetic risk information provided was easy to understand (92% vs 88%, p= 0.523) and influenced their decision on GC uptake (86% vs 78%, p=0.299). More participants also proceeded with GC (47% vs 39%, p=0.526) but none of the results were statistically significant. No significant distress after receiving genetic risk assessment was reported. Patients provided with personalized scores found that the visual (96%) and numerical (90%) forms of risk presentation were more helpful than the qualitative (84%) forms.
Conclusions
These interim results showed that personalized genetic risk assessment using visual and numerical forms of risk presentation is acceptable and may be a useful tool in facilitating the uptake of GC among breast cancer patients.
Clinical trial identification
NMRR ID-21-02298-7JY (IIR).
Editorial acknowledgement
Legal entity responsible for the study
Cancer Research Malaysia.
Funding
AstraZeneca.
Disclosure
C.H. Yip: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Invited Speaker: AstraZeneca. A.F. Abdul Aziz: Financial Interests, Personal, Invited Speaker: Roche; Non-Financial Interests, Personal, Member of Board of Directors, a non-governmental non-profit organsiations: National Cancer Society Malaysia; Non-Financial Interests, Personal, Other, Fellow: College of Surgeons, Academy of Medicine Malaysia; Non-Financial Interests, Personal, Member: Malaysian Oncological Society. W.K. Ho, B.H. Ang: Other, Institutional, Other, Pending ARiCa trademarking: Cancer Research Malaysia. S.Y. Yoon: Financial Interests, Personal, Invited Speaker, Honorarium as invited speaker: AstraZeneca. S. Teo: Financial Interests, Institutional, Research Grant, For ARiCa Study: AstraZeneca; Other, Institutional, Other, Pending ARiCa trademarking: Cancer Research Malaysia. All other authors have declared no conflicts of interest.
Resources from the same session
102P - Enhancing colorectal cancer prevention in high-risk populations through faecal immunochemical test surveillance
Presenter: Li Xie
Session: Poster Display
Resources:
Abstract
103P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
104P - The value of functional MR-imaging signature model for early prediction of chemotherapy response and its guidance for regimen adjustment to improve efficacy
Presenter: Wenhua Li
Session: Poster Display
Resources:
Abstract
105P - A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors
Presenter: Weijian Guo
Session: Poster Display
Resources:
Abstract
106P - Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies
Presenter: Ying Yuan
Session: Poster Display
Resources:
Abstract
107P - Tumor-stromal ratio in a new age fibroblast activated protein PET imaging as a biomarker for prediction of response to neoadjuvant chemoradiotherapy in carcinoma rectum
Presenter: swetha Suresh
Session: Poster Display
Resources:
Abstract
108P - Detection of HER2 overexpression in colorectal cancer: Comparison of a HANDLE classic NGS panel with standard IHC/FISH
Presenter: Lijuan Luan
Session: Poster Display
Resources:
Abstract
109P - Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular status
Presenter: Andrea Pretta
Session: Poster Display
Resources:
Abstract
110P - The correlation between multi-dimensional characteristics of circulating tumor cells (CTC) and treatment response in patients with initially unresectable metastatic colorectal cancer
Presenter: Yu Liu
Session: Poster Display
Resources:
Abstract
111P - Comparison of the efficacy and safety of fruquintinib and fruquintinib combined with immune checkpoint inhibitors in the treatment of metastatic microsatellite stable colorectal cancer: A real-world study
Presenter: Zhiqiang Wang
Session: Poster Display
Resources:
Abstract